PolyPid PYPD 深 滬
已收盤 12-19 16:00:00 美东时间
3.97
+0.050
+1.28%
華盛通- 最 高3.98
- 今 開3.90
- 成交量 4.35万股
- 最 低 3.89
- 昨 收 3.92
- 總市值 6604.02万
- 52周最高 4.07
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.30
- 委 比 -33.33%
- 總股本 1663.48万
- 歷史最高 583.50
- 量 比 0.92
- 振 幅 2.30%
- 歷史最低 2.30
- 每 手 1
- 風險率 0.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PolyPid Appoints Brooke Story As Board Chairman, Effective Dec. 11
PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors,
12-16 21:33
PolyPid Gains FDA Support for D-PLEX100 NDA Submission
An announcement from PolyPid ( ($PYPD) ) is now available. On December 3, 2025,...
12-03 21:57
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
Roth Capital Maintains Buy on PolyPid, Lowers Price Target to $9
Roth Capital analyst Boobalan Pachaiyappan maintains PolyPid (NASDAQ:PYPD) with a Buy and lowers the price target from $10 to $9.
11-14 00:38
PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness
PolyPid ( ($PYPD) ) has shared an announcement. PolyPid Ltd. announced its thir...
11-12 20:56
PolyPid Q3 EPS $(0.37) Beats $(0.44) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.44) by 15.53 percent. This is a 69.67 percent increase over losses of $(1.22) per share from the same
11-12 20:30
Earnings Scheduled For November 12, 2025
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
PolyPid's D-PLEX₁₀₀, designed to prevent surgical site infections (SSIs) via extended, localized antibiotic delivery, has been named "Therapeutics Solution of the Year" by BioTech Breakthrough. With Phase 3 results showing a 58% relative risk reduction in SSIs, the product, leveraging PolyPid's PLEX technology, delivers doxycycline for 30 days directly at the surgical site. Widespread SSIs remain a critical issue, causing extended hospital stays ...
11-06 13:30
PolyPid Announces That Dr. Shmuel Sharoni Will Present Topline Phase 3 Shield II Trial Results For D-PLEX₁₀₀ At The 2025 American College Of Surgeons Clinical Congress In Chicago
PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dr. Shmuel Sharoni will present the topline results from the Company's
09-30 20:50
